Onpattro Injection, Lipid Complex
NDC Package 71336-1000-1
Package Information
Onpattro (patisiran) injection is a medication used to treat nerve problems due to a certain inherited condition (transthyretin-mediated amyloidosis). This formulation utilizes a injection, lipid complex delivery system. Marketed by Alnylam Pharmaceuticals, Inc., this product is identified by NDC 71336-1000 and is authorized under FDA application NDA210922.
Identification & Billing
- RxCUI: 2053524 - patisiran lipid complex 10 MG in 5 mL Injection
- RxCUI: 2053524 - 5 ML patisiran lipid complex 2 MG/ML Injection
- RxCUI: 2053524 - patisiran lipid complex 10 MG per 5 ML Injection
- RxCUI: 2053529 - onpattro 10 MG in 5 ML Injection
- RxCUI: 2053529 - 5 ML patisiran lipid complex 2 MG/ML Injection [Onpattro]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 71336 - Alnylam Pharmaceuticals, Inc.
- 71336-1000 - Onpattro
- 71336-1000-1 - 1 VIAL, SINGLE-DOSE in 1 CARTON / 5 mL in 1 VIAL, SINGLE-DOSE
- 71336-1000 - Onpattro
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Billing & HCPCS Mapping
To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.
Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 71336-1000-1 identifies a specific commercial package of 1 vial, single-dose in 1 carton / 5 ml in 1 vial, single-dose of Onpattro, a human prescription drug labeled by Alnylam Pharmaceuticals, Inc.. This injection, lipid complex is formulated for intravenous use and contains patisiran sodium as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Alnylam Pharmaceuticals, Inc. on August 13, 2018. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to treat nerve problems due to a certain inherited condition (transthyretin-mediated amyloidosis). This condition causes a protein that your body normally makes (transthyretin-TTR), to change shape and build up in different parts of your body, which can affect the nerves, heart, and gut. This medication works by decreasing the buildup of TTR in your body.
How is this Alnylam Pharmaceuticals, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 71336100001. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.
